Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Eicosapentaenoic Acid and Docosapentaenoic Acid

Research Papers that Mention the Interaction

EPA significantly increased platelet EPA (0.2±0.1 vs. 3.3±0.4%) and docosapentaenoic acid (DPA; 2.2±0.3 vs. 2.9±0.3%) concentrations, but not DHA.
Lipids  •  2006  |  View Paper
EPA supplementation increased plasma … of EPA and docosapentaenoic acid (DPAn-3) by 880% and 200%, respectively, and increased plasma δ13C-EPA (-31.5 ± 0.2 to -25.7 ± 0.2) and δ13C-DPAn-3 (-28.9 ± 0.3 to -25.0 ± 0.1) toward δ13C-EPA of the supplement.
The American journal of clinical nutrition  •  2019  |  View Paper
For plasma CE fraction, EPA supplementation significantly increased the concentrations of EPA (days 3 and 6) and DPA (days 6), respectively.
For plasma PL fraction, EPA and DPA supplementation significantly increased the concentrations of EPA and DPA at both days 3 and 6, respectively.
For plasma TAG fraction, supplementation with EPA and DPA significantly increased the concentrations of EPA and DPA at both days 3 and 6, respectively.
For subjects consuming the DPA supplement, the concentrations of both DPA and EPA were significantly increased in RBC PL over a 6-day period, respectively.
Prostaglandins, leukotrienes, and essential fatty acids  •  2019  |  View Paper
This indicates that DPA intake is not a good marker of plasma DPA status (or vice versa), and further research is needed to understand the factors that affect the interconversion of EPA and DPA.
Lipids  •  2019  |  View Paper
The recently uncovered biologic activity of n‐3 DPA docosanoids and their marked modulation by dietary DPA intake reveals a unique and …., Larsen, A. E., Sinclair, A. J., Maddipati, K.R., Cameron‐Smith, D. Divergent shifts in lipid mediator profile following supplementation with n‐3 docosapentaenoic acid … eicosapentaenoic acid.
These data show that dietary n‐3 DPA and EPA have highly divergent effects on human lipid mediator profile, with no overlap in PUFA metabolites formed.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology  •  2016  |  View Paper
The supplementation of highly purified EPA caused a significant increase in the content of plasma EPA and docosapentaenoic acid without affecting that of arachidonic acid (AA) and DHA.
Dermatologica  •  1991  |  View Paper
In resident peritoneal macrophages, docosapentaenoic acid (DPA) was responsible for cyclooxygenase inhibition after EPA supplementation, offering fresh insights into how EPA exerts anti-inflammatory effects indirectly through elongation to 22-carbon DPA.
Proceedings of the National Academy of Sciences  •  2012  |  View Paper
DPA supplementation significantly increased the concentration of DHA in liver and the concentration of EPA in liver, heart and skeletal muscle, presumably by the process of retroconversion.
EPA supplementation significantly increased the concentration of EPA and DPA in liver, heart and skeletal muscle and the DHA concentration in liver.
British Journal of Nutrition  •  2009  |  View Paper
EPA treatment increased EPA and docosapentaenoic acid (DPA) content in plasma and in all the membranes studied.
Lipids  •  1997  |  View Paper